CEO Jason Matuszewski Buys 250,000 Shares of BioStem Technologies, Betting on a Comeback Amid Slumping Stock and Regulatory Scrutiny
CEO Jason Matuszewski’s $0.5 M share buy signals confidence in BioStem Technologies amid a 40% stock decline, but investors must weigh weak fundamentals and regulatory risk.
3 minutes to read